The bone marrow niche keeps puzzling scientists in cancer and regenerative medicine. What elements constitute the niche and how it affects neighbor cells in different disease contexts remain to be a matter of debate and extensive investigation. The translational use of hematopoietic stem cells (HSCs) in transplantation biology poses a challenge, given the propensity of these cells to remain quiescent. Although the niche is a good candidate to exploit for reprogramming HSCs and controlling their expansion, new studies have added to its complexity. In 'Bench to Bedside', Paul S. Frenette and Yuya Kunisaki examine these studies to discuss how new players and their signals are involved in HSC maintenance and what the implications are for the development of HSC-based therapies. Among the alterations occurring in leukemias, metabolic events seem to foster cancer progression but may also be involved in cancer predisposition. Rushdia Z. Yusuf, Ying-Hua Wang and David T. Scadden peruse recent clinical and experimental studies that look at myelodysplastic syndromes and secondary leukemias and argue how metabolic changes in these cancers may not only be cell autonomous but also can emanate from the bone marrow stroma. Targeting this niche may open new avenues to reduce the risk for secondary leukemias in cancer survivors.
The holy grail of hematopoietic stem cell (HSC) biology has been to harness self-renewal to expand stem cells for greater availability of transplantation procedures in people with cancer or hematologic diseases. Despite the advances in transplantation biology, many individuals do not have a suitable allogeneic donor. In these cases, unrelated cord blood-derived HSCs have shown promise as a source of cells for transplantation, but the number of HSCs recovered in a single cord is generally too low for adult transplantation, and infusion of two separate cords still leads to delayed hematopoietic recovery 1 . Thus, the development of methods to readily expand HSCs in vitro would be a major leap forward.
In-depth understanding of the identities and function of each component of the hematopoietic microenvironment at the cellular and molecular levels will be crucial to learn how to properly expand HSCs. This knowledge gap has closed substantially after the concept of a stem cell niche was enunciated more than three decades ago 2 . It has been assumed by many, perhaps wishfully, that a do-it-all niche cell exists in the mammalian bone marrow. This idea comes from the original concept by Schofield 2 and also from strong experimental work in the germline of invertebrates, where specific niche cells are thought to provide the necessary goods to maintain germline stem cells 3 . In the mammalian bone marrow, candidate niche cells including osteoblasts 4 , Cxcl12-abundant reticular cells 5 and nestin-positive mesenchymal stem cells 6 have been reported, suggesting a key role for skeletal precursor cells. Two recent studies have added further complexity to the cellular makeup of putative HSC niches in bone marrow 7, 8 (Fig. 1) .
Yamazaki et al. 7 were searching for microenvironments enabling HSC dormancy in the bone marrow. Cell cycle quiescence is a hallmark of somatic stem cells and a key behavior to protect them from hematopoietic stresses and exhaustion 9 . Transforming growth factorb (TGF-b) is a powerful molecule capable of inducing HSC quiescence through inhibition of the lipid-raft clustering that assembles growth factor signaling microdomains 10 . As it is secreted as an inactive form, active TGF-b is generated locally through local protease activity. If TGF-b were to be crucial in promoting HSC quiescence, one would expect that the putative niche would provide a specific environment for its activation. Yamazaki et al. 7 have found that glial fibrillary acidic protein (GFAP)-positive Schwann cells (which ensheath sympathetic nerve fibers) express b 8 integrin, which promotes metalloproteinase-mediated TGF-b activation. Afferent sympathetic nerves form a complex with nestin-positive cells within the bone marrow, in which the nerve itself may regulate HSC quiescence (Fig. 1) . Unexpectedly, a reduction of HSC frequency in the bone marrow occurred when mice were surgically sympathectomized by ligation of the sympathetic trunk. The authors have suggested that the loss of Schwann cells led to HSC differentiation. Other less invasive, but also less specific, methods of sympathectomy (such as femoral and sciatic neurectomy), however, have not led to such reductions in HSC activity 11 , suggesting the presence of other signals that may collaborate with those provided by the Schwann cells of sympathetic nerves. Although the latter issue still needs to be clarified, the findings support the crucial function of local sympathetic nerves in the regulation of hematopoiesis.
Another study in mice evaluated the cellular source of stem cell factor (SCF), encoded by the kit ligand gene (Kitl), a growth factor required for HSC maintenance in a non-cellautonomous manner 8 . SCF exists in two forms, membrane bound and soluble, due to differential splicing and proteolytic cleavage; however, the membrane-bound form seems to play a prominent part in HSC maintenance 12 . When expressed under the Kitl locus, GFP expression was mostly localized in cells associated with sinusoids, the fenestrated blood vessels within the bone marrow 8 . The authors made tissuerestricted deletions of Kitl or knock-in expression of reporters including GFP in osteoblasts, perivascular cells expressing nestin or leptin receptor (Lepr) and endothelial cells. A reduction of HSC frequency was only found in Leprexpressing perivascular cells and endothelial cells lacking Kitl, suggesting that SCF was provided by both cell types, although the contribution from the former type may be much greater. This study proposed that Lepr-expressing and nestin-expressing cells are distinct, as the deletion of Kitl using transgenic lines expressing Cre under control of the Nes promoter did not elicit the same phenotype. It is important to note, however, that Lepr was among the top 1% most highly expressed genes in sorted nestin-positive mouse cells by microarray analysis 6 , suggesting a potential overlap between the two niche cells, which will require further investigation. Thus, cells associated with the vasculature are the major source of SCF in the bone marrow under steady state. It will be important to evaluate whether the same stromal cells produce the cytokine in situations of regenerative stress, which may shed light on the requirements for building an artificial niche dedicated for HSC expansion.
These two studies bring new exciting angles that add further complexity to bone marrow niches; at the same time, they give us a reminder about the considerable hurdles ahead of us in achieving expansion of HSCs expanded HSCs for clinical use. HSCs require an array of secreted and contact factors-most of which still remain unknown-for their maintenance and proliferation. If these factors are indeed provided by distinct stromal cell types, the challenge of concocting the right ratios of niche constituents to support HSCs for clinical use becomes very substantial. By the same token, one can imagine the translational difficulty in obtaining a renewable source of a good-manufacturing-practice-grade cellular cocktail that would meet the safety thresholds for clinical cell therapy. Further studies will aim at characterizing stromal cell types and, most importantly, the molecular constituents and signals that allow HSC proliferation while maintaining self-renewal.
A major obstacle for future translational HSCbased therapeutics highlighted by the study of Yamazaki et al. 7 concerns the propensity of adult HSCs to remain quiescent. This natural preference was repeatedly shown in several studies where genetic mutations leading to HSC proliferation invariably produce HSC exhaustion 9 . How can we unlock HSCs from their quiescent behavior for the purpose of expansion without reaching exhaustion? It is likely that the coupling of self-renewal and quiescence is not absolute, given that it is not the case for all stem cells; for example, embryonic stem cells can both proliferate and self-renew indefinitely. The ultimate solution, through a greater understanding of the molecular basis of the niche, may lie in some sort of direct or indirect reprogramming of adult (quiescent) HSCs into fetal-like (proliferative) stem cells, a feat that will have to be achieved without increasing the risk of malignancies. Every scientific hurdle, almost by definition, can be overcome. We may be just one breakthrough away from surmounting this one. Cancer survivors have recovered from a brush with death, but their battle is often not over. The rigors of their initial bout with the disease predispose them to a second round, often with a more lethal foe in the form of secondary acute myeloid leukemia (AML). The risk of these events is high after particular types of cancer therapy and in people with 'premalignant' myleodysplastic syndrome (MDS) and myeloproliferative disorder, indicating that patient groups can therefore be assessed for markers that may predict for the fight to come. Approximately 15% of all AML develops secondary to cancer chemotherapy with
